Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683793 | 1.00 | GABRA5 (1.00) | GABRA5RAB9ACYP1A2MAPTALDH1A1 | |
| SCHEMBL2685279 | 0.87 | GABRA5 (0.77) | GABRA5RAB9AALDH1A1PKMKDM4E | |
| SCHEMBL2685284 | 0.87 | GABRA5 (0.77) | GABRA5RAB9AALDH1A1PKMKDM4E | |
| SCHEMBL2683796 | 0.86 | GABRA5 (0.75) | GABRA5RAB9AMAPTALDH1A1HSD17B10 | |
| SCHEMBL4407571 | 0.82 | GABRA5 (1.00) | GABRA5ALDH1A1CSNK1DCSNK1E | |
| SCHEMBL2685727 | 0.82 | GABRA5 (1.00) | GABRA5RAB9AMAPTNPC1 | |
| SCHEMBL2685719 | 0.82 | GABRA5 (1.00) | GABRA5RAB9AMAPTNPC1 | |
| SCHEMBL2683436 | 0.81 | GABRA5 (1.00) | GABRA5RAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL2687504 | 0.77 | GABRA5 (0.62) | GABRA5GRM1PTGER4 | |
| SCHEMBL2687502 | 0.77 | GABRA5 (0.62) | GABRA5GRM1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | claimed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | claimed |
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885RAB9A 1207/4885CYP1A2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.